FDA
-
-
-
-
-
-
-
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
-
-
-
-
-
-
-
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
-
-
-
-
-
-
-
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
-
-
-
-
-
-
-
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
-
-
-
-
-
-
-
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
-
-
-
-
-
-
-
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
-
-
-
-
-
-
-
INmune Bio presents data showing INB03 reduces cancer metastases
-
335,190 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


